Pancreatic Cancer's Dark Shadow Begins to Lift The announcement that a KRAS targeting pill has roughly doubled survival rates for patients with metastatic pancreatic cancer has sent shockwaves through the medical community.
For decades, this disease has been a ticking time bomb, growing undetected in the pancreas before striking without warning.
The grim prognosis – nearly 90% of patients die within five years of diagnosis – had led many to consider it a "graveyard" for future drug development. Recent breakthroughs have changed the narrative.